Holen Sie sich die Stockscreener-App
0.2659
3.52%
-0.0097
Schlusskurs vom Vortag:
$0.2756
Offen:
$0.2756
24-Stunden-Volumen:
188.93K
Relative Volume:
0.37
Marktkapitalisierung:
$8.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.85M
KGV:
-0.1003
EPS:
-2.65
Netto-Cashflow:
$-46.25M
1W Leistung:
-11.28%
1M Leistung:
-29.68%
6M Leistung:
-63.05%
1J Leistung:
-60.55%
1-Tages-Spanne:
$0.2551
$0.2756
1-Wochen-Bereich:
$0.2551
$0.3071
52-Wochen-Spanne:
$0.2551
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Firmenname
Vincerx Pharma Inc
Sektor
Branche
Telefon
650-800-6676
Adresse
260 SHERIDAN AVENUE, PALO ALTO
Vergleichen Sie VINC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VINC | 0.2651 | 8.72M | 0 | -48.85M | -46.25M | -2.65 |
| VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.82 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-01 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-13 | Eingeleitet | Laidlaw | Buy |
| 2021-08-25 | Eingeleitet | B. Riley Securities | Buy |
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Leerink Partnrs Weighs in on Vincerx Pharma FY2024 Earnings - Defense World
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus.com
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - Quartz
Vincerx Pharma Reports Q3 2024 Financial Results - TipRanks
Vincerx Pharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Vincerx Pharma Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Reports Complete Responses in VIP943 Trial, Narrows Q3 Loss to $0.17/Share | VINC Stock News - StockTitan
VINC stock touches 52-week low at $0.32 amid market challenges - Investing.com Canada
SEC Form PRE 14A filed by Vincerx Pharma Inc. - Quantisnow
VINC Stock on the Rise: A Promising Investment - The InvestChronicle
Should investors be concerned about Vincerx Pharma Inc (VINC)? - US Post News
Financial Health Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
Check Out Vincerx Pharma Inc (VINC)’s Trade Data Rather Than the Analysts’ Views - SETE News
Taking a Closer Look At Vincerx Pharma Inc (VINC) Following Its Recent Trade - Knox Daily
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges By Investing.com - Investing.com South Africa
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Wall Street Analyst Initiated Vincerx Pharma Inc [VINC]. What else is Wall St. saying - The DBT News
Vincerx Pharma Inc (VINC) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Leerink Partners Cuts Vincerx Pharma (NASDAQ:VINC) Price Target to $2.00 - Defense World
Vincerx reports two complete responses in VIP943 study By Investing.com - Investing.com Australia
VINC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Vincerx stock tumbles 20% on corporate updates - MSN
Vincerx stock tumbles 20% on corporate updates (NASDAQ:VINC) - Seeking Alpha
Leerink cuts Vincerx Pharma stock target on pipeline update By Investing.com - Investing.com UK
Financial Fitness Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
Vincerx reports two complete responses in VIP943 study - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates - StockTitan
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 2.1% - Defense World
A better buy-in window may exist right now for Vincerx Pharma Inc (VINC) - SETE News
Investing in Vincerx Pharma Inc (VINC) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely - Simply Wall St
Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc. Has $3.38 Million Position in Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval - TipRanks
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024 - MSN
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Acadian Asset Management LLC Sells 36,571 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 31.7% - Defense World
How should investors view Vincerx Pharma Inc (VINC)? – US Post News - US Post News
Vincerx Pharma Inc (VINC) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 29.3% in June - Defense World
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? - Yahoo Finance
Vincerx Pharma Inc Inc. (VINC) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 7.1% - Defense World
Balance Sheet Insights: Vincerx Pharma Inc (VINC)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):